RT Journal Article
SR Electronic
T1 Extreme COVID-19 waves reveal hyperexponential growth and finite-time singularity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.15.21265037
DO 10.1101/2021.10.15.21265037
A1 Pavithran, Induja
A1 Sujith, R. I.
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.10.15.21265037.abstract
AB Coronavirus disease 2019 (COVID-19) has rapidly spread throughout our planet, bringing human lives to a standstill. Understanding the early transmission dynamics helps plan intervention strategies such as lockdowns that mitigate further spread, minimizing the adverse impact on humanity and the economy1–3. Exponential growth of infections was thought to be the defining feature of an epidemic in its initial growth phase4–7; any variation from an exponential growth was described by adjusting the parameters of the exponential model7,8. Here, we show that, contrary to common belief, early stages of extreme COVID-19 waves display an unbounded growth and finite-time singularity accompanying a hyperexponential power-law. The faster than exponential growth phase is hazardous and would entail stricter regulations. Such a power-law description allows us to characterize COVID-19 waves with single power-law exponents, better than piece-wise exponentials. Furthermore, we identify the presence of log-periodic patterns decorating the power-law growth. These log-periodic oscillations may enable better prediction of the finite-time singularity. We anticipate that our findings of hyperexponential growth and log-periodicity will help model the COVID-19 transmission more accurately.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Department of Science and Technology, Government of India under the JC Bose Fellowship JCB/2018/000034/SSCAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://covid19.who.int and https://data.covid19india.org https://data.covid19india.org https://covid19.who.int